Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal: The oncologist
Published: June 09, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Journal: European urology
Published: May 07, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
Journal: Clinical genitourinary cancer
Published: February 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Journal: Clinical genitourinary cancer
Published: September 12, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Journal: European urology oncology
Published: July 04, 2024
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Journal: Cancer medicine
Published: May 18, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
Journal: Clinical genitourinary cancer
Published: April 08, 2024
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Journal: Targeted oncology
Published: March 14, 2024
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Journal: Clinical genitourinary cancer
Published: May 29, 2023
Last Updated: 09/26/2026